IMUNON To Report Topline Results From The Phase 2 OVATION 2 Study With IMNN-001 In Advanced Ovarian Cancer July 30, At ~8:00 a.m. ET
Portfolio Pulse from Benzinga Newsdesk
IMUNON, Inc. (NASDAQ:IMNN) will announce topline results from its Phase 2 OVATION 2 Study with IMNN-001 in advanced ovarian cancer on July 30 at 8:00 a.m. ET. A conference call to discuss the results will follow at 8:30 a.m. ET.
July 29, 2024 | 8:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IMUNON, Inc. will release topline results from its Phase 2 OVATION 2 Study with IMNN-001 in advanced ovarian cancer. The announcement is scheduled for July 30 at 8:00 a.m. ET, followed by a conference call at 8:30 a.m. ET.
The announcement of topline results from a Phase 2 study is a significant event for a clinical-stage biotech company. Positive results could lead to a substantial increase in stock price, while negative results could have the opposite effect. The scheduled conference call indicates the company's readiness to discuss the results in detail, which adds to the importance of this event.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100